logo
Watch SpaceX blast Starship engine ahead of its 10th flight test

Watch SpaceX blast Starship engine ahead of its 10th flight test

Digital Trends5 days ago
SpaceX has successfully completed a single-engine static fire test of its Starship spacecraft, taking it another step closer to the 10th flight test of the entire rocket, comprising the Super Heavy booster and Starship spacecraft.
The test took place at SpaceX's Starbase facility in Boca Chica, Texas, on Thursday, and lasted a matter of seconds. The company shared several image and a video of the test on X.
Starship single-engine static fire demonstrating an in-space burn complete on Pad 1 at Starbase pic.twitter.com/oLjKnAb6dg — SpaceX (@SpaceX) July 31, 2025
Next up is the spacecraft's six-engine static fire, which is expected to take place on Friday. The last time it carried out this particular test, the Starship went up in a massive fireball.
Recommended Videos
The spectacular explosion was attributed to a failure in a nosecone-based pressurized tank containing gaseous nitrogen. The failure caused a catastrophic chain reaction that destroyed the vehicle and damaged the test site. No one was hurt in the incident.
SpaceX has yet to announce a specific target date for the 10th test flight of the Starship — the world's most powerful rocket — but the company's CEO, Elon Musk, said recently that the vehicle would head skyward from Starbase in August.
Shortly before the launch, Musk will give a presentation to update everyone about the progress of the Starship project, with the CEO expected to focus on areas such as engineering, production, and SpaceX's future launch plans.
The Starship first flew in 2023, and the nine flights have produced mixed results for the team developing the 120-meter-tall rocket. But each flight gives engineers a lot to work with, allowing them to refine the design and performance of the rocket.
NASA is planning to use a modified version of the Starship spacecraft to land two astronauts on the moon in the Artemis III mission, which is currently targeted for 2027, though that date could slip. Much depends on the progress made with the Starship's upcoming test flights.
The Starship might also be used for the first crewed mission to Mars, which NASA could launch in the 2030s, though a firm timeline has yet to be announced.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

This AI Stock Has Nearly Tripled in the Last Year
This AI Stock Has Nearly Tripled in the Last Year

Yahoo

time10 minutes ago

  • Yahoo

This AI Stock Has Nearly Tripled in the Last Year

Symbotic (SYM) set a new 52-week high in morning trading on Aug. 5. The stock is showing strong technical momentum with a 100% 'Buy' signal via Barchart. Shares are up more than 170% over the past 52 weeks. Wall Street sentiment is bullish, with multiple 'Strong Buy' ratings and a consensus price target well above current levels. Today's Featured Stock Valued at $33.35 billion, Symbotic (SYM) is an automation technology company reimagining the supply chain with its end-to-end, artificial intelligence-powered robotic and software platform. What I'm Watching I found today's Chart of the Day by using Barchart's powerful screening functions to sort for stocks with the highest technical buy signals; superior current momentum in both strength and direction; and a Trend Seeker 'buy' signal. I then used Barchart's Flipcharts feature to review the charts for consistent price appreciation. More News from Barchart Dear Nvidia Stock Fans, Mark Your Calendars for August 27 Options Traders Expected Palantir Stock's Tamest Earnings Reaction in a Year. Did They Get It Right? Tesla Gains on Elon Musk's New Pay Package. Is TSLA Stock a Buy? Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! SYM checks those boxes. Since the Trend Seeker signaled a buy on May 8, the stock has gained 136.3%. SYM Price vs. Daily Moving Averages: Barchart Technical Indicators for Symbotic Editor's Note: The technical indicators below are updated live during the session every 20 minutes and can therefore change each day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the website when you read this report. These technical indicators form the Barchart Opinion on a particular stock. Symbotic shares hit a new 52-week high on Aug. 5, touching $62.61 in intraday trading. Symbotic has a Weighted Alpha of +213.61. Symbotic has a 100% 'Buy' opinion from Barchart. The stock has gained 172.36% over the past year. SYM has its Trend Seeker 'Buy' signal intact. Symbotic is trading above its 20-, 50-, and 100-day moving averages. The stock made 10 new highs and gained 30.53% in the last month. Relative Strength Index (RSI) is at 72.76%. There's a technical support level around $53.16. Don't Forget the Fundamentals $33.35 billion market capitalization. Revenue is projected to grow 20.96% this year and another 31.43% next year. Earnings are estimated to increase 132.24% next year. Analyst and Investor Sentiment on Symbotic I don't buy stocks because everyone else is buying, but I do realize that if major firms and investors are dumping a stock, it's hard to make money swimming against the tide. It looks like Wall Street analysts are bullish on SYM, and so are most major advisory sites. The Wall Street analysts tracked by Barchart have issued 7 'Strong Buy,' 1 'Moderate Buy,' 9 'Hold,' and 1 'Sell' opinion on the stock. Value Line gives the company its above-average rating with a price target of $74. CFRA's Market Scope rates the stock a 'Strong Buy.' Morningstar thinks the stock is fairly valued. 12,520 investors monitor the stock on Seeking Alpha, which rates the stock a 'Hold.' The Bottom Line on Symbotic Stock Symbotic currently has momentum and is hitting new highs. It has positive sentiment from Wall Street, plus analysts project double-digit increases in revenue and earnings. That said, I caution that SYM is volatile and even speculative in the current environment, which means investors should use strict risk management and stop-loss strategies. Today's Chart of the Day was written by Jim Van Meerten. Read previous editions of the daily newsletter here. Additional disclosure: The Barchart of the Day highlights stocks that are experiencing exceptional current price appreciation. They are not intended to be buy recommendations as these stocks are extremely volatile and speculative. Should you decide to add one of these stocks to your investment portfolio it is highly suggested you follow a predetermined diversification and moving stop loss discipline that is consistent with your personal investment risk tolerance. On the date of publication, Jim Van Meerten did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

MEI Pharma Chooses Not Bitcoin, Not Ethereum, But Litecoin As Treasury Asset
MEI Pharma Chooses Not Bitcoin, Not Ethereum, But Litecoin As Treasury Asset

Yahoo

time10 minutes ago

  • Yahoo

MEI Pharma Chooses Not Bitcoin, Not Ethereum, But Litecoin As Treasury Asset

San Diego-based MEI Pharma (NASDAQ:MEIP) has acquired 929,548 Litecoin (CRYPTO: LTC) tokens, becoming the first U.S.-listed public company to adopt Litecoin as its primary treasury reserve asset. What Happened: The acquisition, valued at approximately $110.4 million as of Aug. 4, marks the launch of a $100 million institutional treasury strategy in collaboration with crypto market maker GSR and Litecoin creator Charlie Lee. The company said it purchased the LTC tokens at an average price of $107.58, positioning the crypto asset as a strategic alternative to traditional reserve holdings. The move follows a broader trend of public firms exploring digital assets as part of long-term capital diversification. 'Litecoin has long embodied sound, scalable, and decentralized money,' said Charlie Lee, who also sits on MEI's board. "By initiating this strategy, MEI is taking a clear, institutional step forward that recognizes Litecoin's role as both a reserve asset and an integral part of global financial systems." MEI's treasury model is being guided by GSR, a leading crypto investment and trading firm, which will advise on market structure, governance, and execution. Also Read: Why Litecoin? The firm cited several reasons behind its decision: 13+ years of uptime: Litecoin remains one of the most reliable blockchains in terms of network availability. Low fees and fast settlements: Ideal for treasury and operational use cases. Ecosystem adoption: Litecoin is already integrated into platforms like PayPal (NASDAQ:PYPL), BitPay, Venmo, and Robinhood (NASDAQ:HOOD), offering significant merchant and user traction. MEI Pharma's move follows in the footsteps of other publicly traded firms holding crypto in treasury, though this is the first such bet on Litecoin. Strategy holds 628,791 Bitcoin ($46.8 billion as of recent filings). Tesla holds 11,509 Bitcoin, representing 0.055% of the total Bitcoin supply. Coinbase (NASDAQ:COIN) holds 11,776 Bitcoin and CleanSpark (NASDAQ:CLSK) controls 12,608 Bitcoin, or about 0.060% of the total supply. Galaxy Digital owns 12,830 Bitcoin, equal to 0.061% of the total supply. Investment firm Metaplanet (OTC:MTPLF) holds 17,595 Bitcoin, worth 0.084% of the global supply. Trump Media & Technology Group Corp. (NASDAQ:DJT) owns 18,430 Bitcoin. Unlike these companies, MEI is the first to exclusively adopt LTC as a primary reserve asset, a notable move given Litecoin's reputation for reliability but generally lower profile in corporate circles compared to BTC or (CRYPTO: ETH). MEI indicated that further changes to its corporate identity are forthcoming, signaling a broader pivot towards fintech and possibly even Litecoin mining. Despite this, the company emphasized its continued focus on its drug candidate pipeline, including voruciclib, a CDK9 inhibitor currently in pre-clinical stages. Read Next: Image: Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article MEI Pharma Chooses Not Bitcoin, Not Ethereum, But Litecoin As Treasury Asset originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store